Welcome!

News Feed Item

New Treatment for Paediatric Crohn's Disease Now Available in the UK

MAIDENHEAD, England, January 16, 2013 /PRNewswire/ --

HUMIRA® (adalimumab) is the first biologic treatment in more than five years to be approved in the European Union for the treatment of severe active paediatric Crohn's disease offering at-home administration after suitable training[1],[2]

AbbVie announced today that HUMIRA® (adalimumab) is now available for the treatment of paediatric patients aged six to 17 years with severe active Crohn's disease (CD) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications to such therapies. [1]

"Paediatric Crohn's disease is a chronic bowel disease that may have a significant impact on a child or young person and his or her family's quality of life," said Dr Richard Russell, Consultant Paediatric Gastroenterologist, Royal Hospital for Sick Children, Glasgow. "The number of children and young people diagnosed with Crohn's disease continues to rise in the UK but the number of treatment options available remains limited. For patients who do not respond to standard therapies, this new treatment option addresses a significant unmet need by offering the flexibility of out of hospital injectable administration, usually by patients or their parents."  

Paediatric Crohn's disease is a chronic condition of the gastrointestinal (GI) tract. In the UK there are currently around 90,000 people living with Crohn's disease, which can affect people of all ages, including children.[3]

As a type of inflammatory bowel disease, it most commonly involves the end of the small intestine and the beginning of the large intestine.[3] In addition to symptoms such as abdominal pain, weight loss and diarrhoea, paediatric Crohn's disease can affect children in several ways unique to this age group, including delayed growth and/or puberty.[4]

Richard Driscoll, Chief Executive of Crohn's and Colitis UK a charity which provides information, support and research for people of all ages affected by inflammatory bowel disease, said "Paediatric Crohn's disease is known to be increasing in frequency among children and young adults of all ages. We welcome this new treatment that is being made available in the UK as the symptoms can be very severe and have a significant debilitating effect on the child and their family."

"Whilst the psychological effects cannot be measured, symptoms, treatment and side effects may mean that childhood and adolescence can be severely disrupted making it difficult for some children to cope emotionally. Physical growth and pubertal development can be delayed, creating an additional problem, particularly in relation to school, college and social life" said Rod Mitchell, Chairman of the Crohn's in Childhood Research Association (CICRA).

Notes to editors

About HUMIRA[1]

HUMIRA® (adalimumab) is a prescription medicine licenced for the treatment of moderate to severe active rheumatoid arthritis, active polyarticular juvenile idiopathic arthritis, active and progressive psoriatic arthritis, severe active ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderately to severely active Crohn's disease and ulcerative colitis in adults, severe active Crohn's disease in paediatric patients, and moderate to severe chronic plaque psoriasis. Please refer to the Humira Summary of Product Characteristics (SmPC) for full product information which can be found at http://www.medicines.org.uk.

Adverse events should be reported. Reporting forms and information can be found at  http://yellowcard.mhra.gov.uk/. Adverse events should also be reported to AbbVie Ltd on +44-(0)1628-774933.

About AbbVie

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ approximately 23,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit http://www.abbvie.co.uk

1.    Humira Summary of Product Characteristics accessed via http://www.medicines.org.uk

2.    European Medicines Agency. Scientific discussion. 2007. Available from: http://www.rcplondon.ac.uk/sites/default/files/documents/national-paediatric-uk-ibd-inpatient-care-audit-report-round-3_0.pdf Last accessed December 2012

3.    NHS CHOICES. Crohn's disease. Available from: http://www.nhs.uk/conditions/crohns-disease/Pages/Introduction.aspx Last accessed December 2012

4.    Mackner, L (2003). "Review: Psychosocial Issues in Pediatric Inflammatory Bowel Disease" J. Pediatr Psychol. 29 (4): 243-257


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that’s no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, will explore how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He wi...
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...
In the enterprise today, connected IoT devices are everywhere – both inside and outside corporate environments. The need to identify, manage, control and secure a quickly growing web of connections and outside devices is making the already challenging task of security even more important, and onerous. In his session at @ThingsExpo, Rich Boyer, CISO and Chief Architect for Security at NTT i3, discussed new ways of thinking and the approaches needed to address the emerging challenges of security i...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, will discuss th...
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, discussed the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insights from the vast t...
Docker containers have brought great opportunities to shorten the deployment process through continuous integration and the delivery of applications and microservices. This applies equally to enterprise data centers as well as the cloud. In his session at 20th Cloud Expo, Jari Kolehmainen, founder and CTO of Kontena, discussed solutions and benefits of a deeply integrated deployment pipeline using technologies such as container management platforms, Docker containers, and the drone.io Cl tool. H...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
There is only one world-class Cloud event on earth, and that is Cloud Expo – which returns to Silicon Valley for the 21st Cloud Expo at the Santa Clara Convention Center, October 31 - November 2, 2017. Every Global 2000 enterprise in the world is now integrating cloud computing in some form into its IT development and operations. Midsize and small businesses are also migrating to the cloud in increasing numbers. Companies are each developing their unique mix of cloud technologies and service...
Cloud adoption is often driven by a desire to increase efficiency, boost agility and save money. All too often, however, the reality involves unpredictable cost spikes and lack of oversight due to resource limitations. In his session at 20th Cloud Expo, Joe Kinsella, CTO and Founder of CloudHealth Technologies, tackled the question: “How do you build a fully optimized cloud?” He will examine: Why TCO is critical to achieving cloud success – and why attendees should be thinking holistically ab...
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, will introduce two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
Recently, IoT seems emerging as a solution vehicle for data analytics on real-world scenarios from setting a room temperature setting to predicting a component failure of an aircraft. Compared with developing an application or deploying a cloud service, is an IoT solution unique? If so, how? How does a typical IoT solution architecture consist? And what are the essential components and how are they relevant to each other? How does the security play out? What are the best practices in formulating...
An increasing number of companies are creating products that combine data with analytical capabilities. Running interactive queries on Big Data requires complex architectures to store and query data effectively, typically involving data streams, an choosing efficient file format/database and multiple independent systems that are tied together through custom-engineered pipelines. In his session at @BigDataExpo at @ThingsExpo, Tomer Levi, a senior software engineer at Intel’s Advanced Analytics ...